Valerie Ramirez

Dynamic clinical research professional with extensive experience at IMA Clinical Research, excelling in regulatory compliance and protocol adherence. Proven ability to manage multiple projects while ensuring subject safety and detailed documentation. Strong problem-solving skills and expertise in electronic data capture drive successful trial outcomes and stakeholder satisfaction.

• National Healthcare Association- Certified Clinical Medical Assistant
• ACRP- Certified Clinical Research Coordinator
• How to conduct Clinical Trials, IATA certified
• Phlebotomy Certified
• IV Certified- State of NM
• Cardiac Arrhythmia Tech
• GCP
• CITI Training

• Clinical Research Coordinator, A Phase 2B, Double-Blind, Multi-Center, Randomized, Comparator-Controlled Trial to Determine the Relative Efficacy, Safety, and Immunogenicity of the Investigational Oral SARS-CoV-2 Vaccine Tablet (XXXXXXX-X.X) Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection, 2025
• Clinical Research Coordinator, A Phase 2, Randomized, Investigator and Participant Blinded, Placebo-controlled, Parallel-group Study to Investigate the Safety, Tolerability, and Preliminary Efficacy of XXX-XXX Treatment in Adult Patients With Alcohol Use Disorder (AUD), 2025
• Clinical Research Coordinator, A Randomized, Double-blind, Multicenter, Placebocontrolled Study of Adjunctive XXXXXXXXXX Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia, 2024
• Clinical Research Coordinator, A US, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of XXXXXXXXXX Nasal Spray for the Acute Treatment of Anxiety Induced by a Public Speaking Challenge in Adult Subjects with Social Anxiety Disorder, with an Open-Label Extension (XXXXXXXX-X), 2024
• Clinical Research Coordinator, A Study of XXXXXXXXXXXX Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional Decline, 2024
• Clinical Research Coordinator, A Phase 3, Randomized, Double-Blind, PlaceboControlled Study to Investigate the Effect of XXXXXXXXXXX on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) Who Have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event – XXXXXXX-XXXXX, 2024
• Clinical Research Coordinator, A Phase 2/3 Double-Blind, Randomized, PlaceboControlled Adaptive Design Trial to Evaluate the Efficacy and Safety of Intravenous XXXXXX in Early Alzheimer's Disease, 2024
• Clinical Research Coordinator, A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a) who have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event – ACCLAIM-Lp(a), 2024
• Clinical Research Coordinator, A Phase 3, randomized, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD, 2023
• Clinical Research Coordinator, A Phase 3, Open-Label Study of Once Daily LY3502970 Compared with Insulin Glargine in Adult Participants with Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4), 2023
• Clinical Research Coordinator, A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared with Placebo in Adult Participants with Obesity or Overweight and Type 2 Diabetes (ATTAIN-2), 2023
• Clinical Research Coordinator, A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults with Obesity, 2023
• Clinical Research Coordinator, A Phase 3, Double-Bline, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily at Bedtime in Patients with Fibromyalgia (Protocol No. TNX-CY-F307), 2022
• Clinical Research Coordinator, A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer’s Disease I5T-MC-AACM., 2022
• Clinical Research Coordinator, Phase III Pivotal, Vagus Nerve Stimulation Using the Setpoint System for Moderate to Severe Rheumatoid Arthritis. The RESET-RA Study. An Operationally seamless, 2-stage, Randomized, Sham- Controlled, Double-Blind, Multicenter, Pivotal Study with A 12-week Follow up. (RA), 2021
• Clinical Research Coordinator, A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-1554 in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response to Biologic and/ or Targeted Synthetic Disease- Modifying Anti-Rheumatic Drugs (b/tsDMARDS) (RA), 2021
• Clinical Research Coordinator, A 12 Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase III Study to Evaluate the Efficacy and Safety of HP-5000 Topical System (Patch) in Subjects with Osteoarthritis Pain of the Knee. (OA), 2021
• Clinical Research Coordinator, Phase 1b, A Multicenter, Open- Label Study To Evaluate the Pharmacokinetics of Certolizumab Pegol In Adults with Active Rheumatoid Arthritis Using an Electrochemiluminescent Imunno-Assay. (RA), 2020
• Clinical Research Coordinator, A Randomized, Placebo Controlled, Double-blind, Multicenter Study to Assess the Efficacy And Safety of Multiple Doses of BMS-986165 in Subjects With Active Psoriatic Arthritis. (PsA), 2019
• Clinical Research Coordinator, A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Phase III Study of Baricitinib in Patients with Systemic Lupus Erythematosus. (SLE), 2019
• Clinical Research Coordinator, A Randomized, Double-Blind, Placebo Controlled Multicenter Phase II Study and Efficacy of RO7123520 as Adjunct Treatment in Patients with Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to TNF-a INhibitors. (RA), 2019
• Clinical Research Coordinator, Phase III, A Multicenter, Randomized , Open-Label Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe of Auto-Injector For the Subcutaneous Self-Injection of Bimekizumab Solution by Subjects with Active Psoriatic Arthritis. (PsA), 2019
• Clinical Research Coordinator, Phase III, A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects with Active Psoriatic Arthritis. (PsA), 2019
• Clinical Research Coordinator, A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Active Reference (Adalimumab) Study Evaluating the Efficacy and Safety of Bimekizumab in the Treatment of Subjects with Active Psoriatic Arthritis. (PsA) PA0010, 2019
• Clinical Research Coordinator, A Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety Of Bimekizumab in the Treatment of Subjects with Active Psoriatic Arthritis. (PsA) PA0011, 2019
• Clinical Research Coordinator, A Randomized, Double-Blind, Parallel-group, Multicenter Study of Secukinumab to Compare 300mg and 150mg at Week 52 in Patients with Ankylosing Spondylitis. (AS), 2018
• Clinical Research Coordinator, A 2-Part Phase II Randomized, Double-Blind, Placebo-Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and Subjects with Active CUtaneous Lupus Erythematosus with or without Systemic Manifestations. (SLE/CLE), 2018
• Clinical Research Coordinator, Phase II oral BTK Inhibitor in RA for Patients that are MTX IR (RA), 2017
• Clinical Research Coordinator, Evaluation of the Efficacy and Safety of GS-5745 as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate regimen in Subjects with Arthritis. (RA), 2017
• Clinical Research Coordinator, A Randomized Double-Blind, Placebo-Controlled, Multicenter, Phase II Proof-of- Concept Study to Evaluate Safety, Tolerability and Efficacy Of GS-9876 in Subject with Active Rheumatoid Arthritis on Methotrexate. (RA), 2017
• Clinical Research Coordinator, Phase 3B, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept in Combination with Methotrexate Compared to Methotrexate Monotherapy in Achieving Clinical Remission in Adults with Early Rheumatoid Arthritis who are Methotrexate Naive (RA), 2016
• Clinical Research Coordinator, Phase III Randomized, A Multicenter, Randomized, Double Blind, Placebo-Controlled 24- Week Study Followed by the Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease Modifying Antirheumatic Drug- Experienced Patients with Active Psoriatic Arthritis (PsA), 2016
• Clinical Research Coordinator, Long-term assessment of Safety, patients with efficacy, pharmacokinetics and Immunology of BI-695501 in rheumatoid arthritis: an Open extension trial for patients who have completed 1297.2 And are eligible for long-term treatment with adalimumab., 2016
• Clinical Research Coordinator, Phase III for Subjects who ‘completed’ Janssen ‘Sirround’ core study. (RA), 2016
• Clinical Research Coordinator, Humira vs. Biosimilar for subjects failing Methotrexate/DMARD monotherapy (RA), 2016
• Clinical Research Coordinator, Phase III study Etanercept monotherapy vs MTX Monotherapy for subjects with PsA. (Psoriatic Arthritis PsA), 2016
• Clinical Research Coordinator, Phase III study of Etanercept ‘early withdrawal’ (RA), 2016
• Clinical Research Coordinator, Phase III, Double Blind, Placebo Controlled study IL-6 drug for subjects who have failed prior TNF therapy (RA), 2015
• Clinical Research Coordinator, A Randomized, Double Blind, Parallel-Group, Phase III study to demonstrate equivalent efficacy And to compare safety and immunogenicity of GP2015 and Enbrel in patients with moderate to severe, active Rheumatoid Arthritis. (RA), 2015
• Clinical Research Coordinator, Phase II, Assessment Of Real-life Patient Handling Experience of BI695501 Administered Subcutaneously with an Autoinjector in Patients with RA: An Open-label, Interventional Clinical Trial Followed by Extension Phase of BI 695501 Administered with a Prefilled Syringe. (RA), 2015
• Clinical Research Coordinator, Phase III study with ‘Simponi’ For Subjects who are currently failing Remicade (RA), 2014
• Clinical Research Coordinator, Double Blind study of B cell Biosimilar vs Rituxan- Part I and Part II (RA), 2013